| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹3 0% | 2500% |
| - | - | 4,500 | ₹40 0% | 1250% |
| - | - | 4,700 | ₹5 0% | 1,1250% |
| - | - | 4,800 | ₹3.55 1.42% | 5,625-4.25% |
| - | - | 4,850 | ₹12.5 0% | 00% |
| - | - | 4,900 | ₹4 -18.36% | 9,125-2.66% |
| 2,0000% | ₹336.5 0% | 5,000 | ₹5.1 -26.08% | 10,625-3.40% |
| - | - | 5,050 | ₹8.55 0% | 00% |
| 6250% | ₹244.45 0% | 5,100 | ₹8.2 -15.02% | 11,50073.58% |
| 6250% | ₹203.7 0% | 5,150 | ₹10.95 -7.59% | 3,37512.5% |
| 3,8750% | ₹334.35 0% | 5,200 | ₹13.3 -15.28% | 30,750-11.19% |
| 1,500-7.69% | ₹283 19% | 5,250 | ₹18 -14.48% | 10,625-5.55% |
| 12,250-6.66% | ₹235.35 -6.62% | 5,300 | ₹24.45 -12.67% | 27,3753.79% |
| 6,000-4% | ₹188.9 -13.28% | 5,350 | ₹34.35 -8.76% | 13,250-5.35% |
| 24,8750.50% | ₹164.55 -6.9% | 5,400 | ₹48.1 -5.03% | 34,375-15.38% |
| 9,375-7.40% | ₹130.1 -10.7% | 5,450 | ₹65 -3.12% | 7,000-3.44% |
| 72,625-12.76% | ₹103.7 -10.37% | 5,500 | ₹85.7 -2.28% | 26,250-3.66% |
| 16,00011.30% | ₹79 -13.8% | 5,550 | ₹112.8 -0.83% | 4,3756.06% |
| 37,250-18.35% | ₹60.9 -14.4% | 5,600 | ₹140.05 -2.13% | 16,0003.22% |
| 3,12531.57% | ₹46.95 -12.4% | 5,650 | - | - |
| 46,500-0.53% | ₹31 -26.27% | 5,700 | - | - |
| 6,2502.04% | ₹25.5 -20.43% | 5,750 | - | - |
| 26,125-23.72% | ₹18.6 -23.45% | 5,800 | ₹300.5 0% | 5000% |
| 5,87511.90% | ₹11.1 -23.44% | 5,900 | ₹388.55 0% | 2500% |
| 18,875-7.92% | ₹7 -17.15% | 6,000 | - | - |
| 3,625-6.45% | ₹4.5 -35.71% | 6,100 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
